Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland by Mueller, Tanja et al.

ORIGINAL ARTICLE
Comparative safety and effectiveness of direct
oral anticoagulants in patients with atrial
ﬁbrillation in clinical practice in Scotland
Correspondence Tanja Mueller, The Farr Institute of Health Informatics Research, Strathclyde Institute of Pharmacy and Biomedical
Sciences, University of Strathclyde, Glasgow, UK. Tel.: +44 (0)141 548 2367; E-mail: tanja.muller@strath.ac.uk
Received 27 April 2018; Revised 6 November 2018; Accepted 8 November 2018
Tanja Mueller1 , Samantha Alvarez-Madrazo1, Chris Robertson2,3, Olivia Wu4 and Marion Bennie1,5
1The Farr Institute of Health Informatics Research, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK,
2Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK, 3Health Protection Scotland, NHS National Services Scotland,
Glasgow, UK, 4Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK, and 5Public Health and Intelligence Strategic Business Unit,
NHS National Services Scotland, Edinburgh, UK
Keywords anticoagulants, atrial ﬁbrillation, clinical effectiveness, DOAC, safety
AIMS
The aim of this study was to compare the clinical effectiveness and safety of direct oral anticoagulants (DOACs) in patients with
atrial ﬁbrillation (AF) in routine clinical practice.
METHODS
This retrospective cohort study used linked administrative data. The study population (n = 14 577) included patients with a
diagnosis of AF (conﬁrmed in hospital) who initiated DOAC treatment in Scotland between August 2011 and December 2015.
Multivariate Cox proportional hazard models were used to estimate hazard ratios of thromboembolic events, mortality and
bleeding events.
RESULTS
No differences between the DOACs were observed with regard to the risk of stroke, systemic embolism or cardiovascular death. In
contrast, the risk of myocardial infarction was higher among patients prescribed apixaban in comparison to those on rivaroxaban
(HR 1.67, 95% CI 1.02-2.71), and all-cause mortality was higher among rivaroxaban patients in contrast to both apixaban (1.22
[1.01–1.47]) and dabigatran (1.55 [1.16–2.05]) patients; rivaroxaban patients also had a higher risk of pulmonary embolism than
apixaban patients (5.27 [1.79–15.53]). The risk of other major bleeds was higher among rivaroxaban patients compared to
apixaban (1.50 [1.10–2.03]) and dabigatran (1.58 [1.01–2.48]) patients; the risks of gastrointestinal bleeds and overall bleeding
were higher among rivaroxaban patients than among apixaban patients (1.48 [1.01–2.16] and 1.52 [1.21–1.92], respectively).
CONCLUSIONS
All DOACs were similarly effective in preventing strokes and systemic embolisms, while patients being treated with rivaroxaban
exhibited the highest bleeding risks. Observed differences in the risks of all-cause mortality, myocardial infarction and pulmonary
embolism warrant further research.
British Journal of Clinical
Pharmacology
Br J Clin Pharmacol (2019) 85 422–431 422
© 2018 The Authors. British Journal of Clinical Pharmacology
published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
DOI:10.1111/bcp.13814
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, pro-
vided the original work is properly cited.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Direct oral anticoagulants (DOACs) are increasingly prescribed to patients with atrial ﬁbrillation in order to prevent
strokes.
• No clinical trials directly comparing the different DOACs have been conducted, and information regarding the compar-
ative effectiveness and safety of DOACs in clinical practice is still limited.
WHAT THIS STUDY ADDS
• This study conﬁrms the comparable effectiveness, but diverging bleeding risk proﬁles of dabigatran, rivaroxaban and
apixaban.
• The study indicates potentially vital differences in the risks of myocardial infarction, pulmonary embolism and mortality
among patients treated with individual DOACs.
Introduction
Atrial ﬁbrillation (AF) is a common arrhythmic disorder par-
ticularly among the elderly, and an independent risk factor
for stroke – increasing it up to ﬁve-fold [1]. Hence, patients
with AF are frequently treated long term with oral anticoagu-
lants in order to prevent strokes.
Vitamin K antagonists (VKAs) such as warfarin have been
used for this purpose for decades; although bleeding events as
a consequence of anticoagulation are not uncommon, VKAs
have proven to be sufﬁciently safe and effective for this indi-
cation [2–4]. However, VKA treatment has limitations: it can
be inconvenient for patients as it requires constant monitor-
ing; adherence to treatment is considered to be rather low
[5]; and there are frequently cases, particularly when patients
are frail or very elderly, when treatment is not initiated de-
spite the presence of multiple stroke risk factors [6, 7]. There-
fore, the direct oral anticoagulants (DOACs) dabigatran,
rivaroxaban, apixaban and edoxaban have been developed
as an alternative means of treatment. Clinical trials, compar-
ing DOACs with warfarin, have proven their safety and efﬁ-
cacy [8–11]; consequently, they have been approved for
stroke prevention in patients with AF, and are now increas-
ingly prescribed to patients in many countries, including
Scotland.
Nevertheless, although a number of indirect comparisons
for the purpose of multiple treatment comparisons of DOACs
have been published, including network meta-analyses facil-
itating indirect comparisons of multiple treatment groups
[12–16], no clinical trials directly comparing the different
DOACs have been conducted; and information regarding
the effectiveness and safety of DOACs in clinical practice is
still limited. Hence, the purpose of this study was to compare
the clinical effectiveness and safety of the different DOACs in
patients with AF in routine clinical practice.
Methods
Study setting
Scotland has a population of approximately 5.4 million
[17], covered by the publicly funded National Health
Service (NHS) Scotland. NHS Scotland is divided into 14 re-
gional Health Boards, responsible for planning and deliver-
ing services to their respective populations [18, 19]. Every
resident registered with a general practitioner (GP) in
Scotland is issued a Community Health Index (CHI) num-
ber, serving as a unique patient identiﬁer throughout the
health system [20].
Study design
The study has been designed as a retrospective cohort study,
using routinely collected administrative data: while prescrip-
tion details originated from the Prescribing Information Sys-
tem (PIS), clinical data were gathered from the Scottish
Morbidity Records/Hospital Inpatients and Outpatient atten-
dance datasets (SMR01 and SMR00); date and cause of death
have been extracted from National Records of Scotland
(NRS). Datasets have been linked via CHI numbers.
PIS was created for payment purposes and combines data
about the drugs as well as the prescriber, the dispenser and the
costs, for all prescriptions issued and dispensed in the com-
munity in Scotland; information relating to drugs is based
on the British National Formulary [21, 22]. The Scottish Mor-
bidity Records are a series of datasets collecting information
about diagnoses and treatment of diseases: SMR01 and
SMR00 contain patient-level data on inpatient/day care dis-
charge episode and appointments in outpatient clinics, re-
spectively. International Classiﬁcation of Disease codes,
10th edition (ICD-10) are used in both datasets to record diag-
nostic details, while Ofﬁce of Population Censuses and Sur-
veys procedural codes, 4th revision (OPCS-4) are used to
record surgical procedures [23, 24]. NRS is the Scottish gov-
ernment department responsible for the registration of life
events such as births and deaths; its main data source is the
civil registration system [25].
Study population
The study population comprised patients with AF, either di-
agnosed or conﬁrmed in secondary care, who started treat-
ment with any DOAC between each drugs’ approval date for
the prevention of stroke in patients with AF in Scotland
(dabigatran: August 2011; rivaroxaban: January 2012;
apixaban: January 2013; edoxaban: October 2015) and
December 2015. A patient’s index date for study inclusion
was the date of ﬁrst recorded prescription for any DOAC.
Patients were followed up until the investigated outcome oc-
curred, the patient died or was removed from a Scottish GP
register for other reasons, or the study end date (31 December
2015), whichever occurred ﬁrst. Patients were censored at the
time of ﬁrst treatment discontinuation; time to discontinua-
tion was calculated using the reﬁll-gap method [26], with an
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admissible supply gap of 28 days and adjusting for previous
oversupply. Censoring for discontinuation included patients
switching from their index drug to a different DOAC. Patients
where alternative indications for treatment with oral antico-
agulants were present (i.e. heart valve replacements, mitral
stenosis, or hip/knee replacement surgery or a venous throm-
boembolism (VTE) during the 6-month period directly pre-
ceding the date of DOAC initiation) were excluded; in
addition, patients were required to have a follow-up period
of at least one day to enable analysis. Speciﬁc inclusion and
exclusion criteria are detailed in supplementary Table S1.
Drug exposure and outcomes
Exposure to speciﬁc DOACs was deﬁned as either yes or no.
Patients initiating treatment with one drug were compared
to patients initiating treatment with any of the other drugs;
due to the censoring of patients at time of ﬁrst treatment dis-
continuation and/or switch between drugs, all patients were
continuously exposed to their index drug throughout their
respective follow-up periods. By focusing solely on the ﬁrst
treatment episode, differences in discontinuation rates and
persistence to treatment between the different DOACs have
been taken into account.
Treatment outcomes have been divided into two separate
categories: effectiveness outcomes and safety outcomes. The
primary effectiveness outcomes comprised stroke – all stroke
(a composite of ischaemic and haemorrhagic stroke), as well
as ischaemic stroke separately – systemic embolism, and
death due to cardiovascular reasons as main clinical end-
points, comparable to the pivotal clinical trials. Also similar
to the trials, secondary outcomes were pulmonary embolism,
transient ischaemic attack, myocardial infarction, and all-
cause mortality; as well as composite effectiveness outcomes
comprising (a) ischaemic stroke and systemic embolism;
and (b) all stroke, systemic embolism and transient ischaemic
attack. Safety outcomes all related to bleeding events, catego-
rized as either major or non-major/minor bleeding in the tri-
als. Due to data availability, bleeding outcomes in this study
have been divided into haemorrhagic stroke (comprising
both intracranial and subarachnoid haemorrhages); other
major bleeds, including other non-traumatic intracranial
haemorrhages and haemorrhages occurring within the chest
or the respiratory or urinary tracts; and gastrointestinal bleed-
ing. A composite outcome of all bleeds – comprising
haemorrhagic stroke, other major bleeds and gastrointestinal
bleeding – has been added in order to evaluate the overall risk
of bleeding. ICD-10 codes used to identify clinical endpoints
are listed in supplementary Table S2.
Patients were censored after a ﬁrst recorded event; how-
ever, all outcomes were analysed separately, meaning that
while patients could have been subject to two different out-
comes (e.g. a stroke and a major bleed), repeat events (i.e. a
second stroke after having already suffered a stroke since ini-
tiating DOAC treatment) were not included in the analysis.
More speciﬁcally, this means that a patient with both a stroke
and a major bleed was included in the stroke analysis up to
the time of ﬁrst stroke, and in the major bleed analysis up to
the time of ﬁrst major bleed; if the stroke came ﬁrst, the major
bleed analysis was not censored at the time of stroke. The
time to event was calculated based on the date of ﬁrst
prescription and date of hospital admission or date of death,
as applicable.
Statistical analysis
Crude incidence rates have been calculated and expressed as
events per 100 person-years. Statistical analysis of treatment
outcomes has been conducted using multivariate Cox pro-
portional hazard models, with time to event measured in
days. Themain exploratory variable was a categorical variable
with three levels, indicating drug exposure (dabigatran,
rivaroxaban or apixaban; no patients have initiated
edoxaban treatment during the study period); binary vari-
ables (0 = no, 1 = yes) indicated the occurrence of an outcome
of interest. A subgroup analysis – comprising patients with no
observed changes in daily dose during the treatment period –
has been performed to remove potential inﬂuences of dosage
changes.
Variables used as covariates were chosen based on differ-
ences in patients’ baseline characteristics, and comprised
socio-demographic factors (sex, age at time of ﬁrst prescrip-
tion, level of deprivation [27]) as well as markers for comor-
bidities (Charlson score [28]), stroke and bleeding risks
(CHA2DS2-VASc [29] and HAS-BLED score [30], respectively),
and polypharmacy (being treated with ﬁve or more drugs
concomitantly). In order to account for observed geographi-
cal variations in prescribing patterns across Scotland, two ad-
ditional variables – describing patients’ place of residence in
terms of Health Board and urban/rural classiﬁcation [31] –
have been included. All covariates were ﬁxed at baseline; de-
tails regarding the calculation of the CHA2DS2-VASc and
HAS-BLED scores can be found in supplementary Table S3.
All analyses were conducted using the R software, version
3.5.1 [32].
Ethical approval
Ethical approval was not required as only non-identiﬁable
routine data were used for this study, and no patient identi-
ﬁers were available to the study team. However, use of the
data has been approved by the appropriate Public Beneﬁt
and Privacy Panel for Health and Social Care [33]. The data
were hosted and managed by the NHS Scotland National Safe
Haven [34].
Results
A total of 18 456 patients with a diagnosis of AF, conﬁrmed in
secondary care, initiated treatment with dabigatran,
rivaroxaban or apixaban during the study period. After ex-
cluding patients with valvular heart disease/heart valve re-
placement (n = 3077) or either a VTE (n = 679) or hip or
knee replacement surgery (n = 220) 6 months prior to their
ﬁrst DOAC prescription, 14 634 patients remained; of these,
a further 57 patients were excluded either because they have
been treated with more than one DOAC simultaneously
(n = 34), and due to having had less than one day of follow-
up (n = 23). Of the 14 577 patients included in the analysis,
6200 (42.5%) were treated with apixaban, 1112 (7.6%) with
dabigatran and 7265 (49.8%) with rivaroxaban. For baseline
characteristics, see Table 1.
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Table 1
Patients’ baseline characteristics, by drug prescribed
Apixaban (n = 6200) Dabigatran (n = 1112) Rivaroxaban (n = 7265) P-valuea
Calendar year of ﬁrst prescription (%)
2011 0 48 (4.3) 0
2012 0 350 (31.5) 439 (6.0)
2013 341 (5.5) 356 (32.0) 1457 (20.1)
2014 1950 (31.5) 246 (22.1) 2497 (34.4)
2015 3909 (63.0) 112 (10.1) 2872 (39.5)
Median time of follow-up [days] (IQR) 188 (74–353) 216 (65–625.5) 243 (94–505) <0.001
Female (%) 2885 (46.5) 410 (36.9) 3321 (45.7) <0.001
Mean age ﬁrst prescription [years] (SD) 73.7 (11.5) 71.1 (12.0) 74.8 (11.0) <0.001
<65 years (%) 1224 (19.7) 299 (26.9) 1190 (16.4)
65–74 years (%) 1696 (27.4) 342 (30.8) 2005 (27.6)
75 years and older (%) 3280 (52.9) 471 (42.4) 4070 (56.0)
Mean Charlson score (SD) 1.4 (1.7) 1.1 (1.5) 1.3 (1.7) <0.001
Mean CHA2DS2-VASc score (SD) 2.9 (1.7) 2.5 (1.8) 3.0 (1.7) <0.001
Comorbidities as included in CHA2DS2-VASc score (%)
b
Congestive heart failure 918 (14.8) 126 (11.3) 1009 (13.9) 0.007
Hypertension 2244 (36.2) 384 (34.5) 2722 (37.5) 0.092
Diabetes mellitus 952 (15.4) 149 (13.4) 1115 (15.3) 0.219
Prior stroke/TIA 908 (14.6) 137 (12.3) 1040 (14.3) 0.125
Vascular disease 1068 (17.2) 161 (14.5) 1339 (18.4) 0.003
Mean HAS-BLED score (SD) 2.1 (1.2) 1.9 (1.2) 2.0 (1.2) <0.001
Conditions as included in HAS-BLED score in addition to hypertension and prior stroke (%)b
Renal disease 947 (15.3) 97 (8.7) 1050 (14.5) <0.001
Liver disease 13 (0.2) <5 18 (0.2) 0.564
Prior major bleeding 587 (9.5) 117 (10.5) 673 (9.3) 0.409
Medication usagec 3153 (50.9) 514 (46.2) 3007 (41.4) <0.001
Alcohol usage 275 (4.4) 55 (4.9) 266 (3.7) 0.025
Polypharmacy (%)d, e 5377 (86.7) 919 (82.6) 6417 (88.3) <0.001
Concomitant medication (%)e
VKA 1810 (29.2) 492 (44.2) 3190 (43.9) <0.001
Antiplatelet drugs 2891 (46.6) 464 (41.7) 2762 (38.0) <0.001
NSAIDs 471 (7.6) 92 (8.3) 460 (6.3) 0.004
Digoxin 1471 (23.7) 286 (25.7) 1739 (23.9) 0.355
Beta-blocker 4353 (70.2) 700 (62.9) 4814 (66.3) <0.001
Anti-diabetic drugs 812 (13.1) 135 (12.1) 985 (13.6) 0.383
Insulin 216 (3.5) 36 (3.2) 292 (4.0) 0.175
Statins 3413 (55.0) 560 (50.4) 3908 (53.8) 0.012
IQR, interquartile range; NSAID, non-steroidal anti-inﬂammatory drug; SD, standard deviation; TIA, transient ischaemic attack; VKA, vitamin K an-
tagonist (acenocoumarol, phenindione, warfarin sodium)
aChi-square or ANOVA comparing all groups
bDeﬁnitions are provided in supplementary Table S3
cMedication predisposing to bleeding, assessed during the 6-month period prior to the ﬁrst prescription (comprises anti-platelet drugs and NSAIDs)
dTaking ﬁve or more different drugs concomitantly
eDuring a 6-month period directly preceding initiation of DOAC treatment
DOAC use in AF patients in Scotland
Br J Clin Pharmacol (2019) 85 422–431 425
During the study period, 192 ischaemic strokes, 18 sys-
temic embolisms, and 613 deaths due to cardiovascular rea-
sons occurred, in addition to 54 haemorrhagic strokes, 229
gastrointestinal bleeds, and 368 other bleeding events; crude
incidence rates by drug prescribed are presented in Table 2.
Clinical effectiveness
No differences between the DOACs were observed with re-
spect to either primary effectiveness outcomes or the com-
posite outcomes; there were, however, differences between
drugs regarding three of the secondary effectiveness out-
comes. Patients using rivaroxaban were 5.27 times [95% CI
1.79–15.53] more likely than patients being treated with
apixaban to experience a pulmonary embolism; in contrast,
apixaban patients were more likely to have a myocardial in-
farction than patients using rivaroxaban, with a hazard ratio
of 1.67 [95% CI 1.02–2.71]. The use of rivaroxaban was asso-
ciated with higher risks of all-cause mortality as compared
to both apixaban and dabigatran (apixaban: HR 0.82 [95%
CI 0.68–0.99], dabigatran: HR 0.65 [95% CI 0.49–0.86]). See
Table 3 for details; hazard ratios and 95% conﬁdence intervals
for comparisons with regard to secondary effectiveness out-
comes are shown in Figure 1. Results are also presented in
supplementary Table S4.
Safety
There were no signiﬁcant differences between DOACs regard-
ing haemorrhagic stroke, but there were with respect to gas-
trointestinal and other bleeds, as well as the composite
outcome of all bleeding. Gastrointestinal bleeds as well as
other major bleeds were 1.48 [95% CI 1.01–2.16] and 1.50
[95% CI 1.10–2.03] times more likely among patients using
rivaroxaban than among apixaban patients, respectively;
the overall bleeding risk – including all bleeding events –
was 52% higher among patients being treated with
rivaroxaban than among patients receiving apixaban (HR
1.52, 95% CI 1.21–1.92). While there were no differences
between dabigatran and both apixaban and rivaroxaban with
regard to gastrointestinal bleeds, the risk of other major
bleeds was higher among rivaroxaban patients as compared
to dabigatran (HR 1.58.95% CI 1.01–2.48). For details, see
Table 3; comparisons of hazard ratios and 95% conﬁdence in-
tervals relating to safety outcomes are shown in Figure 2. Re-
sults are also presented in supplementary Table S5.
Subgroup analysis
A total of 1066 patients (7.3%) experienced dosage changes
during the treatment period; while 645 patients (4.4%) re-
ceived reduced doses as compared to their initial dose, 384
patients (2.6%) increased dosage during the follow-up period,
and 37 patients (0.3%) were subject to more than one dosage
change.
After excluding these patients, the majority of results
were consistent with the main analysis: no differences were
observed between the DOACs regarding ischaemic/all stroke,
systemic embolism, transient ischaemic attack, composite ef-
fectiveness outcomes or haemorrhagic stroke, while ﬁndings
indicated differences in the risks of pulmonary embolism,
all-cause mortality and overall bleeding.
Results differed, however, with respect to the other out-
comes. In the subgroup analysis, no differences were found
in the risks of myocardial infarction and gastrointestinal
bleeding; or between rivaroxaban and dabigatran regarding
othermajor bleeds. In contrast, a higher risk of cardiovascular
death was observed in rivaroxaban patients as compared to
patients being treated with dabigatran (HR 1.54 [95% CI
1.05–2.28]). Details are presented in supplementary Table S6.
Discussion
This was the ﬁrst study in Scotland using linked data to ana-
lyse the clinical effectiveness and safety of DOAC treatment
in patients with AF, and one of a growing number of
Table 2
Crude incidence rates for all outcomes except composites, by drug prescribed
Apixaban (n = 6200) Dabigatran (n = 1112) Rivaroxaban (n = 7265)
No. of events IR/100 PY No. of events IR/100 PY No. of events IR/100 PY
Ischaemic stroke 67 1.66 19 1.62 106 1.61
Systemic embolism 5 0.12 2 0.17 11 0.17
Death, cardiovascular 196 4.83 39 3.30 378 5.70
Pulmonary embolism 7 0.17 0 0.0 29 0.44
Transient ischaemic attack 23 0.57 4 0.34 40 0.61
Myocardial infarction 77 1.91 7 0.59 57 0.86
All-cause mortality 305 7.51 61 5.16 622 9.38
Haemorrhagic stroke 16 0.39 3 0.25 35 0.53
Gastrointestinal bleeding 69 1.71 22 1.88 138 2.10
Other major bleeds 104 2.59 23 1.97 241 3.71
IR, incidence rate; PY, person years
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international observational studies directly comparing the
individual DOACs – either focusing on safety [35, 36], or
analysing both safety and effectiveness [37–41]. As one of
the few nationwide studies conducted outside the US thus
far, it provides exceptional population coverage. In addition,
it offers a comprehensive overview of DOAC treatment
outcomes by including all drugs available during the study
period, as well as evaluating both their clinical effectiveness
and safety.
The main study ﬁndings are, by and large, comparable to
previously published results: although bleeding risks differ
between individual drugs, all DOACs are similarly effective
Figure 1
Adjusted hazard ratios and 95% conﬁdence intervals for comparions of secondary effectiveness outcomes. CI, conﬁdence interval; HR, hazard ratio
Table 3
Hazard ratios with 95% conﬁdence intervals, multivariate models
Reference: rivaroxaban Apixaban P-value Dabigatran P-value
Ischaemic stroke 1.06 [0.68–1.64] 0.808 1.18 [0.70–2.01] 0.535
All stroke 0.89 [0.60–1.31] 0.557 1.01 [0.62–1.64] 0.981
Systemic embolism 0.59 [0.15–2.26] 0.441 1.54 [0.31–7.60] 0.596
Death, cardiovascular 0.92 [0.72–1.17] 0.476 0.71 [0.50–1.02] 0.065
Pulmonary embolism 0.19 [0.06–0.56] 0.003 n/a
Transient ischaemic attack 0.75 [0.38–1.49] 0.413 0.63 [0.22–1.81] 0.390
Myocardial infarction 1.67 [1.02–2.71] 0.040 0.73 [0.32–1.68] 0.465
All-cause mortality 0.82 [0.68–0.99] 0.042 0.65 [0.49–0.86] 0.003
Composite Aa 0.98 [0.65–1.49] 0.941 1.18 [0.71–1.96] 0.517
Composite Bb 0.85 [0.61–1.19] 0.340 0.98 [0.64–1.51] 0.936
Haemorrhagic stroke 0.53 [0.24–1.15] 0.106 0.43 [0.12–1.53] 0.194
Gastrointestinal bleeding 0.68 [0.46–0.99] 0.045 1.03 [0.63–1.68] 0.907
Other major bleeds 0.67 [0.49–0.91] 0.010 0.63 [0.40–0.99] 0.045
All bleeds (composite) 0.66 [0.52–0.83] <0.001 0.74 [0.54–1.02] 0.067
aIschaemic stroke + systemic embolism
bAll stroke + transient ischaemic attack + systemic embolism
DOAC use in AF patients in Scotland
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in preventing strokes and systemic embolisms. Nevertheless,
a number of unexpected results emerged from this study:
ﬁrst, rivaroxaban seems to be associated with an increased
risk of all-cause mortality as compared to apixaban and
dabigatran; second, patients treated with apixaban appeared
to have a higher risk of experiencing a myocardial infarction
than patients treated with rivaroxaban; and third, apixaban
might potentially be more effective in preventing pulmonary
embolisms than rivaroxaban.
In this study, no signiﬁcant differences between DOACs
were found in the risks of strokes, systemic embolism,
transient ischaemic attacks or combinations thereof – in line
with the majority of previously published research. Other ob-
servational studies also found no differences in the risk of
stroke between dabigatran and rivaroxaban [38], the combi-
nation of stroke/systemic embolism between apixaban and
dabigatran [37] or between any of the DOACs [41], or a com-
posite outcome of stroke, systemic embolism and death
across all DOACs [39], principally conﬁrming conclusions
made based on indirect comparisons between DOACs using
clinical trial data [12–14]. Unlike the results with regard to
these primary outcomes, which have shown high agreement
across studies, ﬁndings relating to secondary outcomes were
nevertheless varied. The risk of all-cause mortality, for in-
stance, was 55% higher among rivaroxaban patients than
among dabigatran patients in this study (albeit with a
relatively wide conﬁdence interval around the HR), and
comparable ﬁndings have been reported before: 43% in a na-
tionwide Danish study [38]; and 44% in an observational
study from Taiwan [40]. Results with respect to comparative
risks of myocardial infarction differed, however, between
studies. While our study found a higher risk among patients
using apixaban as compared to rivaroxaban, other observa-
tional studies found no differences or did not report them
[38, 40], while indirect comparisons – based on clinical trials
data – suggested higher risks in dabigatran in comparison to
apixaban and/or rivaroxaban [12, 13]. Moreover, the risks of
pulmonary embolisms have rarely been analysed; an indirect
comparison of apixaban and dabigatran found no difference
between the DOACs [12].
Due to the disparity of secondary effectiveness outcomes
used across studies – both in terms of what has been used,
and how it has been deﬁned – and the overall still limited
number of studies directly comparing DOACs thus far, there
is only restricted potential to compare results. Consequently,
any reasons for observed differences in the risks of all-cause
mortality, myocardial infarction and especially pulmonary
embolism are difﬁcult to discern. A suggested explanation
for differences in all-cause mortality was selective prescribing
for rivaroxaban based on the relatively higher-risk population
included in the ROCKET-AF trial [38]; due to our study design
and the data available for analysis, unobserved differences in
patient characteristics, linked to the prescribing or non-
prescribing of speciﬁc drugs, were most likely contributing
factors. Similarly, considering the divergence of ﬁndings be-
tween the overall study population and the subgroup analysis
comprising patients not subject to dosage changes, observed
differences in myocardial infarction might have been due to
differences in patient characteristics; however, as reasons for
dosage changes were unknown, additional interpretations
of results would be speculative. Furthermore, pulmonary
embolisms were very rare events during the study period
(n = 36), and the treatment groups in our study were quite dif-
ferent in size, with considerably fewer patients having initi-
ated treatment with dabigatran (n = 1112) than with either
apixaban (n = 6200) or rivaroxaban (n = 7265) – resulting in
no pulmonary embolism having occurred among dabigatran
patients during the study period.
Figure 2
Adjusted hazard ratios and 95% conﬁdence intervals for comparions of safety outcomes. CI, conﬁdence interval; HR, hazard ratio
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While differences across DOACs with respect to the risk
of haemorrhagic strokes were not signiﬁcant in this study,
the risks of gastrointestinal bleeding, other major non-fatal
bleeds, and bleeding overall were 48%, 50% and 52%
higher among patients using rivaroxaban than among
apixaban patients, respectively; there were, however, no
differences between apixaban and dabigatran in any of
the safety outcomes, and observed differences between
rivaroxaban and dabigatran were inconsistent. Similar
ﬁndings have been reported before, albeit with some
variation in individual results. Several previous studies have
highlighted differences in bleeding risks between
rivaroxaban and apixaban, with risks for gastrointestinal
bleeding [35, 37, 39], other major bleeding [35, 36, 41]
and overall bleeding risks [37, 39] all signiﬁcantly higher
among rivaroxaban patients. However, other studies also
reported bleeding risks to be higher among rivaroxaban
patients than among patients using dabigatran [38–41], a
ﬁnding that was observed for other bleeds but not gastroin-
testinal bleeding in our study; this could, however, be due
to different deﬁnitions of bleeding being used. As in this
study, several other studies reported no differences in bleed-
ing events between apixaban and dabigatran [36, 37, 39];
most other studies also did not ﬁnd any differences with
regard to haemorrhagic stroke.
Strengths and limitations
This study has several strengths. As access to health care in
Scotland is universal, electronic patient records are available
for the entire population; records can be easily and reliably
linked due to the presence of a unique patient identiﬁer;
and the validity and accuracy of the data stored in these re-
cords have been established [21, 42, 43].
Nevertheless, there are also some limitations to consider.
First of all, patients to be included in the study have been
identiﬁed in secondary care only, meaning that patients diag-
nosed and treated exclusively in primary care – potentially
with less severe representations of AF – were not captured.
The impact of not including these patients on hazard ratios
when comparing DOACs with each other was, however, most
likely small. As current treatment guidelines do not recom-
mend speciﬁc DOACs based on varying levels of disease
severity, the non-inclusion of patients should have been in-
dependent of the drug they received when initiating DOAC
treatment. Second, as the data used for analysis were not col-
lected speciﬁcally for the purpose of this study but stemmed
from a limited set of administrative records, not all desirable
information was available; identiﬁcation of endpoints, for ex-
ample, had to rely on ICD-10 codes available from hospital
discharge and death records, with possible implications on
the accuracy of ﬁndings – particularly regarding bleeding
events. While this might potentially have resulted in an
underestimation of the bleeding risks associated with DOAC
use, its impact on hazard ratios is likely limited. Furthermore,
as information regarding indication for prescribing was not
available, patients might have been included in this study
who had AF but were treated with DOACs for other reasons;
however, by excluding patients with recorded diagnoses of al-
ternative indications for treatment, this should have been
kept to a minimum, thus limiting the effect on results. Third,
adjustment for covariates was done with covariates scored at
baseline only, even though the use of medication potentially
impacting bleeding risks (such as NSAIDs) while being treated
with DOACs could have affected the accuracy of ﬁndings. As
NSAIDs as well as aspirin are available over-the-counter with-
out a prescription in Scotland, full adjustments for use of
these drugs was, however, not feasible. And ﬁnally, the analy-
sis assumed that effects of the covariates were consistent
across all DOACs; this might not necessarily be the case, with
potential implications on the accuracy of ﬁndings. In addi-
tion, as with all observational studies, associations between
exposure and outcomes might not have been causal. While
efforts have been made to reduce the impact of confounding
factors as far as possible, unmeasured confounding could,
nevertheless, have inﬂuenced the ﬁndings.
Conclusion
In general, this study has mostly conﬁrmed what has been re-
ported before: all DOACs were similarly effective in
preventing strokes and systemic embolisms in patients with
atrial ﬁbrillation, but the bleeding proﬁles differ slightly be-
tween drugs – with rivaroxaban showing the highest overall
risk of bleeding. Nevertheless, the study also indicated poten-
tially vital differences in the risks of all-cause mortality and
myocardial infarction between the DOACs, and provided a
new signal with regard to pulmonary embolism, warranting
further research.
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